Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.
Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.
复制标题
免疫细胞在非小细胞肺癌中的预后意义：荟萃分析
DOI：
10.18632/oncotarget.24835
复制
发表时间：
2018-05-15
期刊：
影响因子：
--
通讯作者：
Soong R
中科院分区：
文献类型：
--
作者：
Soo RA;Chen Z;Yan Teng RS;Tan HL;Iacopetta B;Tai BC;Soong R
肿瘤相关免疫细胞在非小细胞肺癌（NSCLC）中具有预后作用，但研究结果相互矛盾。根据NSCLC患者的定位确定免疫细胞的预后作用。对树突状细胞（DC）、肿瘤相关巨噬细胞（TAM）、肥大细胞（MC）、自然杀伤（NK）细胞、T和B细胞以及肿瘤CTLA-4和PD-L1研究进行了系统性文献综述和荟萃分析。我们分析了96篇文章（n= 21，752例患者）。随着肿瘤DC的增加，（总生存期（OS）风险比（HR）0.55; 95%置信区间（CI）0.44-0.68），NK细胞（OS HR 0.45; 0.31-0.65），TAM（OS HR 0.33; 0.17-0.62），M1 TAM（OS HR 0.10; 0.05-0.21），CD 3 + T细胞（疾病特异性存活（DSS）HR 0.64; 0.48-0.86），CD 8 + T细胞（OS HR 0.78; 0.66-0.93），B细胞（OS HR 0.65; 0.42-0.99）和基质DC增加（DSS HR 0.62; 0.47-0.83），NK细胞（DSS HR 0.51; 0.32-0.82），M1 TAM（OS HR 0.63; 0.42-0.94）、CD 4 + T细胞（OS HR 0.45; 0.21-0.94）、CD 8 + T细胞（OS HR 0.77; 0.69-0.86）和B细胞（OS HR 0.74;0.56-0.99）。基质M2 TAM（OS HR 1.44; 1.06-1.96）和TNM（无复发生存期（RFS）HR 1.80; 1.34-2.43）的结局较差。肿瘤PD-L1与更差的OS（1.40; 1.20-1.69）、RFS（1.67）和DFS（1.24）相关。肿瘤和间质DC、NK细胞、M1 TAM、CD 8 + T细胞和B细胞与改善的预后相关，而肿瘤PD-L1、间质M2 TAM和Treg细胞的预后较差。需要更高质量的研究来确认。
Tumor-associated immune cells are prognostic in non-small cell lung cancer (NSCLC) but findings have been conflicting. To determine the prognostic role of immune cells according to localization in NSCLC patients. A systematic literature review and meta-analysis was performed on dendritic cell (DC), tumor associated macrophages (TAM), mast cells (MC), natural killer (NK) cells, T and B cells and tumor CTLA-4 and PD-L1 studies. We analysed 96 articles (n= 21,752 patients). Improved outcomes were seen with increased tumor DCs (overall survival (OS) hazard ratio (HR) 0.55; 95% confidence interval (CI) 0.44–0.68), NK cells (OS HR 0.45; 0.31–0.65), TAMs (OS HR 0.33; 0.17–0.62), M1 TAMs (OS HR 0.10; 0.05–0.21), CD3+ T cells (disease specific survival (DSS) HR 0.64; 0.48–0.86), CD8+ T cells (OS HR 0.78; 0.66–0.93), B cells (OS HR 0.65; 0.42–0.99) and with increased stroma DC (DSS HR 0.62; 0.47–0.83), NK cells (DSS HR 0.51; 0.32–0.82), M1 TAMs (OS HR 0.63; 0.42–0.94), CD4+ T cells (OS HR 0.45; 0.21–0.94), CD8+ T cells (OS HR 0.77; 0.69–0.86) and B cells (OS HR 0.74;0.56–0.99). Poor outcomes were seen with stromal M2 TAMs (OS HR 1.44; 1.06–1.96) and Tregs (relapse free survival (RFS) HR 1.80; 1.34–2.43). Tumor PD-L1 was associated with worse OS (1.40; 1.20–1.69), RFS (1.67) and DFS (1.24). Tumor and stroma DC, NK cells, M1 TAMs, CD8+ T cells and B cells were associated with improved prognosis and tumor PD-L1, stromal M2 TAMs and Treg cells had poorer prognosis. Higher quality studies are required for confirmation.